Latest Options News

Livium Ltd has locked in exclusive worldwide rights to a cutting-edge microwave technology from the University of Melbourne, promising high recovery rates and energy savings in rare earth and platinum group metals extraction.

Genmin Limited has launched a A$25.7 million equity raising to advance its Baniaka iron ore project in Gabon, aiming for a final investment decision by mid-2026. The raise includes strategic collaboration with PowerChina and offers attaching options to investors.

Genmin Limited has locked in A$25.7 million through a two-tranche placement, including significant director loan conversions, to advance its flagship Baniaka iron ore project towards production.

Critica Limited has raised A$8 million in an oversubscribed placement to accelerate development of its Jupiter rare earths project, positioning itself as a key supplier of critical minerals for emerging technologies.

Island Pharmaceuticals has secured FDA confirmation that its antiviral Galidesivir can proceed under the Animal Rule pathway for Marburg virus, qualifying for a lucrative Priority Review Voucher. This regulatory milestone accelerates the drug’s path to approval and potential government stockpile inclusion.

Spacetalk launches its subscription-based Freedom Platform, aiming to transform family safety tech and hit $20-25 million in annual recurring revenue by 2026. The new app connects multiple generations, expanding beyond smartwatches into a broader digital ecosystem.

Cann Group Limited reminds eligible shareholders that its Share Purchase Plan (SPP) closes today, offering new shares at a discount plus free attaching options, pending shareholder approval.

Algorae Pharmaceuticals has launched a Loyalty Options Offer, allowing eligible shareholders to purchase options at a nominal price, aiming to reward loyalty and support future growth funding.

Melbana Energy has begun mobilisation for drilling the Amistad-11 well in Cuba’s Block 9, aiming to restore and improve production after formation damage impacted a key well.

Algorae Pharmaceuticals has announced a non-renounceable Loyalty Options Offer to eligible shareholders, aiming to raise up to $337,678 before costs, with potential additional capital of $4.7 million if all options are exercised. The capital raise supports the company’s pharmaceutical and AI research and development ambitions.

Race Oncology has announced pivotal new clinical trials for its lead asset RC220, aiming to accelerate regulatory approval in Acute Myeloid Leukemia and tackle resistance in Non-Small Cell Lung Cancer.

Elders Limited has announced a fully franked ordinary dividend of AUD 0.18 per share for the half-year ending September 2025, accompanied by a Dividend Reinvestment Plan offering a modest discount.